Vendor, Waltham, MA
Entasis Therapeutics, Inc.
UEI P6NKP5BBSUH3, CAGE 7JD21
1 award and -$259,639 obligated between September 23, 2025 and August 18, 2026, 100% under full and open competition, against 12.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | -$259,639 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N93020C00017Definitive Contract, September 23, 2025, Full and Open Competition, 12 offers | National Institutes of Health NiaidNational Institutes of Health | To Identify and Develop a Non-Beta-Lactam PBP Inhibitor (Nbp) with Broad Spectrum of Activity Against MDR Gram-Negative Eskape Pathogens.NAICS 541715, PSC AN12 | -$259,639 |
- Places of performance
- Massachusetts
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 2 across 1 awards